SCHEMBL3772620

SCHEMBL3772620

CN1CC(N2CC3C(CNCc4cccc(C(F)(F)F)c4)C3C2)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 3/20 0.47
PRMT6 Q96LA8 3/20 0.47
P2RX7 Q99572 1/20 0.43
DPP7 Q9UHL4 1/20 0.42
TEAD1 P28347 3/20 0.42
ALKBH5 Q6P6C2 1/20 0.42
FTO Q9C0B1 1/20 0.42
SCN8A Q9UQD0 1/20 0.41
EGFR P00533 1/20 0.41
LMNA P02545 1/20 0.40
GALR3 O60755 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ATM Q13315 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3777124 0.93 CARM1 (0.51) CARM1PRMT6P2RX7DPP7TEAD1
SCHEMBL3783229 0.87 P2RX7 (0.42) CARM1PRMT6P2RX7DPP7TEAD1
SCHEMBL3770725 0.86 CARM1 (0.49) CARM1PRMT6P2RX7DPP7TEAD1
SCHEMBL15966985 0.84 CARM1 (0.49) CARM1PRMT6ATM
SCHEMBL3777511 0.83 CXCR4 (0.45) CARM1PRMT6P2RX7
SCHEMBL3776355 0.82 P2RX7 (0.44) P2RX7
SCHEMBL3776690 0.79 CARM1 (0.45) CARM1PRMT6P2RX7DPP7TEAD1
SCHEMBL3778065 0.78 ATM (0.36) CARM1PRMT6TEAD1ATM
SCHEMBL5513104 0.78 DPP7 (0.47) CARM1PRMT6P2RX7DPP7TEAD1
SCHEMBL5513143 0.77 OPRM1 (0.45) CARM1PRMT6DPP7TEAD1ALKBH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 CARM1 2561/4885PRMT6 1238/4885P2RX7 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.